Cigarette smoking is an important risk factor for pulmonary emphysema. In vitro experiments document cigarette smoke-induced inactivation of alpha 1-proteinase inhibitor, a protein which is thought to protect the lung interstitium against the deleterious action of neutrophil elastase. To assess the relevance of this in in vitro findings, we have measured the functional activity of alpha 1-proteinase inhibitor collected by bronchoalveolar lavage from twenty healthy volunteers (10 heavy smokers and 10 non-smokers). The total inhibitor concentration was measured by radial immunodiffusion. The active inhibitor concentration was determined by virtue of its elastase inhibitory capacity. We used pure and active site-titrated porcine pancreatic elastase and a kinetic assay with succinyl-trialanine-p-nitroanilide in order to get reliable and accurate results. In smokers and in non-smokers the percentage of functionally active alpha 1-proteinase inhibitor in bronchoalveolar lavage fluid is 54 +/- 12 and 38 +/- 14%, respectively. This difference is not significant. Serum alpha 1-proteinase inhibitor is 100% active in both groups. Our data disagree with previous reports suggesting the presence of fully active alpha 1-proteinase inhibitor in bronchoalveolar lavage fluid of non-smokers and of partially active inhibitor in the lavage fluid of smokers.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0009-8981(83)90009-8 | DOI Listing |
Vet Med Int
November 2024
Department of Veterinary Medicine, School of Veterinary and Zootechnics, Universidade Federal de Goiás, Rodovia Goiânia-Nova Veneza, km 8, Campus Samambaia, Goiânia 74690-900, Goiás, Brazil.
Enteropathies are prevalent in dog internal medicine, and their diagnosis involves a lengthy process. One of the tests requested is for biomarkers, which are important as they can provide data on intestinal functionality, intensity of inflammation, and response to treatment, and can help determine the prognosis. This study aimed to conduct a literature review on the main serum and fecal intestinal biomarkers in dogs and proposed to refine the correlations between these indicators and enteropathies.
View Article and Find Full Text PDFHeliyon
June 2024
Ross Pierce MD, LLC, 1330 West Avenue Unit 506, Miami Beach, FL 33139, USA.
Clinical benefit of Alpha-Proteinase Inhibitor (Human) (A-PI) products for Alpha-antitrypsin deficiency (AATD) is uncertain, based on a systematic review of observational studies and randomized controlled trials (RCTs) in AATD of Alpha-Proteinase Inhibitor (Human) (A-PI) products. At the recommended dose, A-PI products raise its serum concentration but do not normalize levels. Observational studies suggest A-PI might modestly slow progression of airflow limitation in patients with intermediate airflow obstruction, a finding not confirmed by three placebo-controlled RCTs of limited power, which showed non-significant rates of forced expiratory volume in 1Â s (FEV) change favoring placebo.
View Article and Find Full Text PDFFront Pharmacol
November 2023
Hospital Pharmacy Department, Hospital Universitario Costa del Sol, Marbella, Spain.
Intravenous augmentation therapy with human alpha-1 proteinase inhibitor for the management of respiratory disease is recommended for people with alpha-1 antitrypsin deficiency (AATD) who are nonsmokers or former smokers. Augmentation therapy usually requires weekly administration at the hospital or clinic and poses an additional burden for patients due to interference with daily life, including work and social activities. Self-administration is a useful alternative to overcome this limitation, but there is a lack of published information on clinical outcomes.
View Article and Find Full Text PDFPulm Pharmacol Ther
December 2023
Takeda Development Center Americas, Inc., Cambridge, MA, United States.
Introduction: The recommended standard dose for α-proteinase inhibitor (A1PI) augmentation therapy is 60 mg/kg once-weekly (QW) intravenous (IV) infusions that aim to maintain systemic A1PI levels >11 μM, the biochemical efficacy threshold, in patients with α-antitrypsin deficiency (AATD). However, this standard dose may not be optimal for all patients. Body weight-based dosing, alternative dosing regimens, and treatment interruption periods were evaluated using population pharmacokinetic (PopPK) modeling and simulations.
View Article and Find Full Text PDFThe universal proteinase inhibitor α2-macroglobulin (α₂-MG) exhibiting antiviral and immunomodulatory activities, is considered as an important participant in the infectious process. The activity of α₂-MG in the new coronavirus infection and post-covid syndrome (long COVID) has not been studied yet. We examined 85 patients diagnosed with community-acquired bilateral polysegmental pneumonia developed under conditions of a new coronavirus infection SARS-CoV-2.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!